Rational approach to identify newer caspase-1 inhibitors using pharmacophore based virtual screening, docking and molecular dynamic simulation studies

McIlwain, 2013, Caspase functions in cell death and disease, Cold Spring Harb. Perspect. Biol., 5, 1, 10.1101/cshperspect.a008656 Denes, 2012, Caspase-1: is IL-1 just the tip of the ICEberg?, Cell Death Dis., 3, 1, 10.1038/cddis.2012.86 Dinarello, 2011, Interleukin-1 in the pathogenesis and treatment of inflammatory diseases, Blood, 117, 3720, 10.1182/blood-2010-07-273417 Randle, 2001, ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs, Expet Opin. Invest. Drugs, 10, 1207, 10.1517/13543784.10.7.1207 Hallegua, 2002, Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases, Ann. Rheum. Dis., 61, 960, 10.1136/ard.61.11.960 Garcia-Calvo, 1998, Inhibition of human caspases by peptide-based and macromolecular inhibitors, J. Biol. Chem., 273, 32608, 10.1074/jbc.273.49.32608 Siegmund, 2003, Pralnacasan (vertex pharmaceuticals), Idrugs, 6, 154 Stack, 2005, IL converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients, J. Immunol., 175, 2630, 10.4049/jimmunol.175.4.2630 MacKenzie, 2010, The potential for caspases in drug discovery, Curr. Opin. Drug Discov. Dev., 13, 568 Laufersweiler, 2005, Synthesis and evaluation of tricyclic pyrrolopyrimidinones as dipeptide mimetics: inhibition of interleukin-1b-converting enzyme, Bioorg. Med. Chem. Lett., 15, 4322, 10.1016/j.bmcl.2005.06.046 Ellis, 2006, Synthesis and evaluation of thiazepines as interleukin-1b converting enzyme (ICE) inhibitors, Bioorg. Med. Chem. Lett., 16, 4728, 10.1016/j.bmcl.2006.07.016 Wang, 2007, Synthesis and evaluation of unsaturated caprolactams as interleukin-1b converting enzyme (ICE) inhibitors, Bioorg. Med. Chem., 15, 1311, 10.1016/j.bmc.2006.11.011 Harter, 2004, The design and synthesis of sulfonamides as caspase-1 inhibitors, Bioorg. Med. Chem. Lett., 14, 809, 10.1016/j.bmcl.2003.10.065 Soper, 2006, Synthesis and evaluation of novel 8,5-fused bicyclic peptidomimetic compounds as interleukin-1b converting enzyme (ICE) inhibitors, Bioorg. Med. Chem., 14, 7880, 10.1016/j.bmc.2006.07.056 Oppong, 2005, Discovery of novel conformationally restricted diazocan peptidomimetics as inhibitors of interleukin-1b synthesis, Bioorg. Med. Chem. Lett., 15, 4291, 10.1016/j.bmcl.2005.06.050 Smellie, 1995, Poling: promoting conformational variation, J. Comput. Chem., 16, 171, 10.1002/jcc.540160205 Brooks, 1983, CHARMM: a program for macromolecular energy, minimization, and dynamics calculations, J. Comput. Chem., 4, 187, 10.1002/jcc.540040211 Chhabria, 2012, Discovery of novel acyl coenzyme a: cholesterol acyltransferase inhibitors: pharmacophore-based virtual screening, synthesis and pharmacology, Chem. Biol. Drug Des., 80, 106, 10.1111/j.1747-0285.2012.01384.x Kristam, 2005, Comparison of conformational analysis techniques to generate pharmacophore hypotheses using catalyst, J. Chem. Inf. Model., 45, 461, 10.1021/ci049731z Li, 2000 Athar, 2016, Pharmacophore model prediction, 3D-QSAR and molecular docking studies on vinyl sulfones targeting Nrf2-mediated gene transcription intended for anti-Parkinson drug design, J. Biomol. Struct. Dyn., 34, 1282, 10.1080/07391102.2015.1077343 Amaravadhi, 2015, Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase, Mol. Divers., 19, 529, 10.1007/s11030-015-9591-5 Lone, 2017, Identification of Mycobacterium tuberculosis enoyl-acyl Carrier protein reductase inhibitors: a combined in-silico and in-vitro analysis, J. Mol. Graph. Model., 76, 172, 10.1016/j.jmgm.2017.07.005 Irwin, 2005, ZINC–a free database of commercially available compounds for virtual screening, J. Chem. Inf. Model., 45, 177, 10.1021/ci049714+ Kumar, 2015, Pharmacophore modeling, in silico screening, molecular docking and molecular dynamics approaches for potential alpha-delta bungarotoxin-4 inhibitors discovery, Phcog. Mag., 11, S19, 10.4103/0973-1296.157670 Kumar, 2016, Multi-level structure-based pharmacophore modelling of caspase-3-non-peptide complexes: extracting essential pharmacophore features and its application to virtual screening, Chem. Biol. Interact., 254, 207, 10.1016/j.cbi.2016.06.011 Ioakimidis, 2008, Benchmarking the reliability of QikProp. Correlation between experimental and predictedvalues, QSAR Comb. Sci., 27, 445, 10.1002/qsar.200730051 Fahr, 2006, Tethering identifies fragment that yields potent inhibitors of human caspase-1, Bioorg. Med. Chem. Lett, 16, 559, 10.1016/j.bmcl.2005.10.048 Rotonda, 1996, The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis, Nat. Struct. Biol., 3, 619, 10.1038/nsb0796-619 Agniswamy, 2007, Plasticity of S2-S4 specificity pockets of executioner caspase-7 revealed by structural and kinetic analysis, FEBS J., 274, 4752, 10.1111/j.1742-4658.2007.05994.x Blanchard, 2000, Caspase-8 specificity probed at subsite S(4): crystal structure of the caspase-8-Z-DEVD-cho complex, J. Mol. Biol., 302, 9, 10.1006/jmbi.2000.4041 Pradeep, 2012, A rational approach to selective pharmacophore designing: an innovative strategy for specific recognition of Gsk3β, Mol. Divers., 16, 553, 10.1007/s11030-012-9387-9 Chen, 2014, An in silico protocol for identifying mTOR inhibitors from natural products, Mol. Divers., 18, 841, 10.1007/s11030-014-9543-5 Choubey, 2016, A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking,density functional and molecular dynamics simulation study, J. Mol. Graph. Model., 70, 54, 10.1016/j.jmgm.2016.09.008 Jasuja, 2014, Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach, Mol. Divers., 18, 253, 10.1007/s11030-013-9497-z Halgren, 2004, Glide: a new approach for rapid, accurate docking and scoring 2. Enrichment factors in database screening, J. Med. Chem., 47, 1750, 10.1021/jm030644s Raghu, 2014, Virtual screening and discovery of novel Aurora kinase inhibitors, Curr. Top. Med. Chem., 14, 2006, 10.2174/1568026614666140929151140 Shivakumar, 2010, Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field, J. Chem. Theor. Comput., 6, 1509, 10.1021/ct900587b Deniz, 2016, A systematic methodology for large scale compound screening: a case study on the discovery of novel S1PL inhibitors, J. Mol. Graph. Model., 63, 110, 10.1016/j.jmgm.2015.11.004